https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28587 Tue 08 Jan 2019 15:13:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19723 Sat 24 Mar 2018 07:53:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5249 Sat 24 Mar 2018 07:44:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34430 -/- murine colitis treated with vehicle or HIF-stabilizing prolyl-hydroxylase inhibitors (PHDi). IL12B promoter analysis was performed to examine hypoxia-responsive elements. Immunoblot analysis of murine and human LPL supernatants was performed to characterize the HIF/IL-12p40 signaling axis. We observed selective induction of IL-12p40 following PHDi-treatment, concurrent with suppression of Th1 and Th17 responses in murine colitis models. In the absence of IL-12p40, PHDi-treatment was ineffective. Analysis of the IL12B promoter identified canonical HIF-binding sites. HIF stabilization in LPLs resulted in production of IL-12p40 homodimer which was protective against colitis. The selective induction of IL-12p40 by HIF-1α leads to a suppression of mucosal Th1 and Th17 responses. This HIF-IL12p40 axis may represent an endogenously protective mechanism to limit the progression of chronic inflammation, shifting from pro-inflammatory IL-12p70 to an antagonistic IL-12p40 homodimer.]]> Mon 20 Feb 2023 14:56:13 AEDT ]]>